Drug intelligence / Profile preview

carboplatin + cixutumumab + paclitaxel

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Intravenous

Overview

The combination of carboplatin, cixutumumab, and paclitaxel is a treatment regimen that has been studied in clinical trials for advanced non-small cell lung cancer (NSCLC). This combination includes two chemotherapy drugs (carboplatin and paclitaxel) along with cixutumumab, which is a monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R). In clinical trials, patients typically received: Carboplatin at an area under the curve (AUC) of 6 intravenously, Paclitaxel 200 mg/m² intravenously on day 1 every 3 weeks, and Cixutumumab intravenously every 2 weeks.

Other names: cixutumumab

Targets

TUBB (Tubulin (alpha and beta subunits))IGF-1R (Insulin-like growth factor 1 receptor)DNA

Beyond the preview

Go deeper on carboplatin + cixutumumab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + cixutumumab + paclitaxel.

Explore the full profile